CD8A and neoplasm: Additionally, miRNA-200c can lower the number of T-regulatory cells, increase CD4+ and CD8+ T cells within tumors, and enhance the proliferation and effector functions of tumor-specific CD8+ T cells by targeting the PD-1/PD-L1 immune checkpoint pathway [47].